Gastrointestinal stromal tumors (GISTs) represent a rare tumor entity that occurs in the muscular layer of the digestive tract. These tumors commonly metastasize to the liver and peritoneum, and ...

GISTs are solid tumors, primarily in the stomach, characterized by KIT and EGFR mutations, with Gleevec as a key treatment. Recent advancements in GIST treatment include multiple TKIs, such as Sutent, ...

Dr. Breelyn Wilky explains that personalized treatments are helping improve outcomes for patients with gastrointestinal stromal tumors. Personalized treatment is helping improve outcomes for patients ...

A recent study offering a comprehensive view of the genome and transcriptome of gastrointestinal stromal tumors (GISTs) has introduced a new, multi-omics-based molecular classification of these tumors ...

Less than 5% of GI stromal tumors (GISTs) are driven by the loss of the succinate dehydrogenase (SDH) complex, resulting in a pervasive DNA hypermethylation pattern that leads to unique clinical ...

A recent study offering a comprehensive view of the genome and transcriptome of gastrointestinal stromal tumors (GISTs) has introduced a new, multi-omics-based molecular classification of these tumors ...

16.5 months median progression free survival (mPFS) for bezuclastinib plus sunitinib compared to 9.2 months mPFS for sunitinib monotherapy (HR=0.50, CI: 0.39-0.65; p<0.0001) 46% Objective Response ...

Second-line treatment patterns and outcomes of advanced gastrointestinal stromal tumor: A real-world study. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...

June 6, 2011 (Chicago, Illinois) — Extended adjuvant treatment with imatinib (Gleevec) improves survival in patients with high-risk gastrointestinal stromal tumors (GIST). Imatinib administered for 3 ...

These study authors hope their findings will inform future research on gastrointestinal stromal tumors (GIST) and close care gaps for minority patient populations. Unfavorable trends in the diagnosis ...